34803-68-4

Basic information

• Product Name: 1-(2-PYRAZINYL)-PIPERAZINE
• Synonyms: 1-(2-PYRAZINYL)-PIPERAZINE;BUTTPARK 82\08-01;TIMTEC-BB SBB005549;(PYRAZIN-2-YL)-PIPERAZINE;RARECHEM AH CK 0184;1-piperazinylpyrazine;1-(Pyrazin-2-yl)piperazine;1-(Pyrazin-2-yl)piperazine 98%
• CAS NO: 34803-68-4
• Molecular Formula: C₈H₁₂N₄
• Molecular Weight: 164.21
• EINECS: 252-221-9
• Mol File: 34803-68-4.mol

Chemical Properties

• Boiling Point: 105-108 °C (0.37505 mmHg)
• Flash Point: 150.042 °C
• Appearance: Yellow/Crystalline Powder or Chunks
• Density: 1.139 g/cm³
• Vapor Pressure: 0.000245mmHg at 25°C
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 8.63±0.10(Predicted)
• CAS DataBase Reference: 1-(2-PYRAZINYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-PYRAZINYL)-PIPERAZINE(34803-68-4)
• EPA Substance Registry System: 1-(2-PYRAZINYL)-PIPERAZINE(34803-68-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 37/39-26-36
• Hazardous Substances Data: 34803-68-4(Hazardous Substances Data)

Usage

Chemical Properties

yellow crystalline powder or chunks

InChI:InChI=1/C8H12N4/c1-2-11-8(7-10-1)12-5-3-9-4-6-12/h1-2,7,9H,3-6H2/p+1

Upstream product

• 110-85-0 piperazine 
• 14508-49-7 2-chloropyrazin 
• 622386-07-6 tert-butyl 4-(pyrazin-2-yl)piperazine-1-carboxylate 

Downstream Products

• 131323-58-5 7-[3-(2,3,5,6-Tetrahydro-[1,2']bipyrazinyl-4-yl)-propoxy]-chromen-4-one 
• 169881-55-4 {2-[(2-bromo-4-isopropyl-phenyl)-ethyl-amino]-6-methyl-pyrimidin-4-yl}-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-methanone 
• 634469-50-4 1-[2-[4-(2-Pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile 
• 634469-57-1 tert-butyl [1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methylcarbamate 
• 634469-74-2 4-(4-chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile 
• 852936-54-0 tert-butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl](methyl)carbamate 
• 634469-90-2 4-(3-chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile 
• 89007-60-3 2',6'-dichloro-4-(2-pyrazinyl)-1-piperazinecarboxanilide 
• 480991-27-3 C₂₈H₃₃N₇O₄ 
• 887275-86-7 Ethyl 3-phenyl-3-(5-{[4-(2-pyrazinyl)-1-piperazinyl]carbonyl}-1H-benzimidazol-1-yl)propanoate 
• 548768-59-8 4-(Pyrazin-2-yl)-piperazine-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester 

Relevant articles and documents

Pd-Catalyzed Synthesis of Piperazine Scaffolds under Aerobic and Solvent-Free Conditions

A facile Pd-catalyzed methodology providing an efficient synthetic route to biologically relevant arylpiperazines under aerobic conditions is reported. Electron donating and sterically hindered aryl chlorides were aminated to afford yields up to 97%, with examples using piperazine as solvent, illustrating an ecofriendly, cost-effective synthesis of these privileged structures.

Parallel synthesis of N-arylpiperazines using polymer-assisted reactions

A series of N-arylpiperazines were prepared in a parallel fashion using palladium-catalyzed cross-coupling, or nucleophilic aromatic displacement chemistries, and polymer-assisted sequestration and purification techniques as key steps.

Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; p is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents an aromatic group selected from: the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.

Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use

The invention relates to compounds of formula: and also to the salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, with affinity for and selectivity towards the arginine-vasopressin V1b receptors and/or for the ocytocin receptors and, furthermore, for certain compounds, affinity for the V1a receptors. The invention also relates to the process for preparing them, to the intermediate compounds of formula (IV) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for preparing medicinal products.

Piperazine compounds and medicinal use thereof

The present invention relates to a piperazine compound of the formula wherein R1and R2are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4and R5are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6and R7are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8and R9are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.

New μ-opioid receptor agonists with piperazine moiety

New μ-opioid receptor (MOR) agonists containing piperazine and homopiperazine moieties in the structures were synthesized and their affinities to and agonist potencies on MOR were evaluated. Among the synthesized compounds, 4-[4-(2-methoxyphenyl)piperazin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide (20Aa) showed the highest affinity to the human MOR expressed in Chinese hamster ovary (CHO)-K1 cells, and the highest agonist potency on the MOR in isolated guinea-pig ileum preparation.

Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

This invention relates to compounds of Formula I STR1 which are useful in association with a pharmaceutical carrier as antiatherosclerotic agents. In addition, various compounds of Formula I are useful inhibitors of cell proliferation.

Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones

This invention relates to compounds of Formula I STR1 which are useful as antiatherosclerotic agents and inhibitors of cell proliferation for the treatment of proliferative diseases. In addition, various compounds of Formula I are useful inhibitors of platelet aggregation.

2,3-Dihydro-3-[4-(substituted)-1-piperazinyl]-1H-isoindol-1-ones

Pyrazinoisoindolone derivatives of the formula STR1 wherein R1 is lower alkyl, phenyl, diphenylmethyl, pyridinyl, pyrimidinyl, pyrazinyl or pyrazinyl substituted with a lower alkyl, lower alkoxy or halo; and R2 is hydrogen, lower alkyl or di(lower)alkylamino(lower)alkyl are useful as antihypertensive agents.

Piperazinylpyrazines with central serotoninmimetic activity.

A series of 2-(1-piperazinyl)pyrazines was synthesized and evaluated for central serotonin-like activity. The most interesting member of the series, 6-chloro-2(1-piperazinyl)pyrazine (3a), had pharmacological properties characteristic of potent central serotoninmimetic activity and only weak peripheral serotoninmimetic action. Structural similarities between 3a and serotonin are discussed.